The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

Journal of Infectious Diseases

Volumn 184, Issue 1, 2001, Pages 37-42

  Veldkamp, Agnes I ^a   Harris, Marianne ^c,d   Montaner, Julio S G ^c,d   Moyle, Graeme ^e   Gazzard, Brian ^e   Youle, Mike ^f   Johnson, Margaret ^f   Carlier, Hilde ^g   Van Leeuwen, Remko ^b   Beijnen, Jos H ^a   Lange, Joep M A ^b   Reiss, Peter ^b   Hoetelmans, Richard M W ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d ST PAUL S HOSPITAL   (Canada)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g Boehringer Ingelheim   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STEADY STATE; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0035399659     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320998     Document Type: Article

References (22)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. The ATLANTIC study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
3. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005)
4. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team
5. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues
6. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group
7. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddI): A very simple, safe, and effective once-daily regimen
8. Efavirenz
9. Nevirapine: A review of its development, pharmacological profile and potential for clinical use
10. Rapid determination of neviraplne in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection
11. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
12. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1 infected individuals
13. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine 200 mg/day
14. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
15. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period
16. The effect of plasma drug concentrations on HIV-I clearance rate during quadruple therapy
17. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
18. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
19. Population pharmacokinetics of efavirenz in phase II studies and relationships with efficacy
20. High exposure to nevirapine is associated with a higher initial HIV-1 clearance rate a higher likelihood to reach undetectability and prolonged suppression of HIV-1 replication
21. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immuno-deficiency virus infection